The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Current and Emerging Pharmacotherapy for Fibromyalgia
Open accessAbstract
Introduction . Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered . The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion . Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, it is compliant with the generally poor efficacies of drugs currently used in FM therapy, but also with the relatively higher efficacy of gabapentinoids [7,140].”
From Fibromyalgia pathogenesis explained by a neuroendocrine multistable model (2024) · cites this paper as [140]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For what concerns FM, both pharmacological and nonpharmacological therapies are generally disappointing, providing very limited benefit to FM patients [4,140,155,156].”
From Fibromyalgia pathogenesis explained by a neuroendocrine multistable model (2024) · cites this paper as [140]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“اکنون شواهدی وجود دارد که برای درمان فیبرومیالژیا از چندین گزینه دارویی مثل داروهای ضدافسردگی و ضدتشنج و درمان غیردارویی مثل درمان شناختی رفتاری استفاده میشود ] 8 [ .”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Evidence for a central component of post-injury pain hypersensitivity
Woolf, C. J. (1983) · Nature · doi:10.1038/306686a0 · Cited by 2,157
EULAR revised recommendations for the management of fibromyalgia
Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209724 · Cited by 1,566 · cited 2×
“did not find them of proven benefit [70], and hence, they are not included in the revised 2016 EULAR recommendations [6].”
BackgroundThe NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · cited 1×
“One example of such an initiative is the Research Domain Criteria (RDoC) of the NIAMH, which attempts to create an integrative framework for the research, classification, and future treatment of mental disorders, while incorporating evidence ranging from genomics through circuits, with the goal of eventually developin…”
BackgroundEULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752 · cited 1×
“Despite the EULAR recommendations for management of FMS from 2008, recommending the consideration of dopamine agonists [8], a meta-analysis conducted by Sommer et al.”
MethodYarnitsky, D. (2010) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32833c348b · Cited by 745 · cited 1×
“+us, medications that modulate levels of these neurotransmitters in the CNS have the potential to improve CPM and reduce central sensitization [40, 41].”
BackgroundPractical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663 · cited 1×
“+e THC:CBD therefore determines the product’s overall effect [71].”
BackgroundCrofford, L. J., Rowbotham, M. C., Mease, P. J., Russell, I. J., Dworkin, R. H., Corbin, A. E., Young, J. P., LaMoreaux, L., Martin, S. A., Sharma, U., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20983 · Cited by 652 · cited 1×
“However, compared to placebo, it was not found to significantly improve complaints of fatigue in some trials, and none of the trials indicated any improvement in depressive symptoms [20, 21, 53].”
ResultYunus, M. B. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.09.003 · Cited by 648
Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity
Napadow, V., LaCount, L., Park, K., As‐Sanie, S., Clauw, D. J., & Harris, R. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27497 · Cited by 645 · cited 2×
“Indeed, increased connectivity between different brain areas is a known phenomenon in FMS [46].”
Background
Flagged first, then by citations
Research works printed but not linked: 4
- 2008, German Medical Science, 6
- 2000, Journal of Pharmacology and Experimental Therapeutics, 293, 607
- 2014, Neuroendocrinology Letters, 35, 198
- 2011, PLoS One, 6
Cited by
Sorted by citations
Items 101–122 of 122
TERAPIAS ALTERNATIVAS NO TRATAMENTO DE FIBROMIALGIA: UMA REVISÃO DE LITERATURA
Araújo, A. F. P., & Amâncio, N. D. F. G. (2023) · Acta Biologica Brasiliensia. · doi:10.18554/acbiobras.v6i1.7248
Well-Being Therapy for Fibromyalgia
Olivero, A., Cuniberti, F., & Leombruni, P. (2024) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001773 · Cited by 1
Fibromialgia: Manifestaciones neuropsiquiátricas y abordaje terapéutico en la atención primaria
Gruezo, P., Cusme-Diaz, N., León-Llanos, H. A., Benavides-López, A., & Morquecho, V. L. Y. (2022) · Revista Reumatología al Día. · doi:10.62484/rad.v16i3.5261
TERAPIA FARMACOLÓGICA CONTEMPORÂNEA E EMERGENTE DA FIBROMIALGIA: UM PANORAMA GERAL DO ESTADO DA ARTE
Mota, M. M. M., ANJOS, L. E. S. D., GUIMARÃES, A. D. C., & BOMFIM, I. D. S. (2024) · Jornada Científica da Faculdade Estácio de Canindé · doi:10.55811/jocec2024-1/36476
Demoulin, C., Costes, C., Sadok, M., Grosdent, S., Kaux, J., & Vanderthommen, M. (2024) · Sensors · doi:10.3390/s25010134
Percepção dos profissionais do AMASF sobre a saúde mental de pacientes com fibromialgia
Rodrigues, M. E. S., Cardoso, C. D. S., Wessler, B. G., Tuon, L., Ceretta, L. B., & de Morais, G. L. (2024) · Revista Remecs - Revista Multidisciplinar de Estudos Científicos em Saúde · doi:10.24281/reremecs2024.9.15.372387
Discovery of Target Genes for Fibromyalgia through Bioinformatics Analysis
Mao, G., & Zhang, B. (2025) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2025057263
Treatment of Fibromyalgia - duloxetine or pregabalin?
Bujak, M., Rulewska, N. M., Grabowski, F., Siemko, J., Neska, D., Prystacka-Szar, D., Stadler-Szajda, J., Czyżnikiewicz, A., Stołowski, W., & Waśniowska, M. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.57856 · Cited by 1
Carruyo, A. J., Yi, P., Patel, B. T., & Ackerman, R. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-86057-7_6
Association between overnutrition and cognitive function in women with fibromyalgiaPreprint
Arias-Álvarez, G., Guzmán, C., Carvajal-Parodi, C., González-Escobar, A., & GONZÁLEZ-GONZÁLEZ, D. (2025) · Research Square · doi:10.21203/rs.3.rs-6838101/v1
Fibromyalgia and Primary Care Providers’ Plan of Care
Casseus, K., Cabahug, I. N. K. V., Owusu, B., Atraga, C. F., & Balthazar, M. S. (2025) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2025.105461
Hamdan, A., Sataloff, R. T., Hawkshaw, M. J., & Ghzayel, L. (2025) · Springer eBooks · doi:10.1007/978-3-031-97751-0_15
What drug treatments are available?
Spickett, G. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198962137.003.0009
Pérez, I. M. M., & Pérez, S. E. M. (2025) · Nutrition and Health · doi:10.1177/02601060251369916
Association between overnutrition and cognitive function in Chilean women with fibromyalgia
Arias-Álvarez, G., Guzmán, C., Carvajal-Parodi, C., González-Escobar, A., & GONZÁLEZ-GONZÁLEZ, D. (2025) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-025-00356-y
“…used by the patients, a majority use of GABAergic, analgesics, and antidepressants is observed, which is consistent with what is described in the literature, where reference is made to the use of these drugs as a basis for the symptomatic treatment of pain, anxiety, and depression [34, 35].”
Liu, Q., 文传兵, Dai, Y., Ma, T., Liu, M. M., Jia, Z., Luo, F., & Wang, D. (2026) · Journal of Pain Research · doi:10.2147/jpr.s605429
Mechanism of Action of Opioid Drugs in Analgesia
Yin, Y. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202623702001
Liberty, M., Ginting, A. R., Darlan, D. M., Liberty, P., & Gohtama, S. (2026) · Reumatologia/Rheumatology · doi:10.5114/reum/217148
“However, pharmacological intervention alone provides limited benefit, with long-term side effects such as dizziness, somnolence, headache, weight gain, and edema [9, 10].”
Barrot, M. (2025) · Dunod eBooks · doi:10.3917/dunod.poisb.2025.01.1428
Horticultural therapy for the management of fibromyalgia: a narrative review
Shimol, J. B. (2026) · Exploration of Musculoskeletal Diseases · doi:10.37349/emd.2026.1007131
Harte, S. E., Arnold, L. M., Ichesco, E., Peltier, S., Cecil, K. M., Kaplan, C. M., Pluimer, B. R., Sridhar, A., Larkin, T. E., Schrepf, A., et al. (2026) · PAIN Reports · doi:10.1097/pr9.0000000000001489
“76 Although preliminary, NYX-2925 reduced daily pain intensity, fatigue, and fibromyalgia impact, suggesting NMDAR modulation may be a viable option.”
Spinetti, D., Sarlo, M., Sfriso, P., Ramonda, R., Bindoli, S., Ghisi, M., Mapelli, D., Sergi, G., RUI, M. D., & Devita, M. (2026) · Pain Research and Management · doi:10.1155/prm/1462017
“Other options include amitriptyline, gabapentin, and naltrexone [53– 56].”
Metadata
- Authors
- Tzadok, R., & Ablin, J. N.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Tzadok, Roie
- Venue
- Pain Research and Management
- Publisher
- Wiley
- Published
- 2020-02-11
- Volume
- 2020
- Pages
- 1-9
- ISSN
- 1203-6765 (ISSN-L)
- 1918-1523
- PMC
- PMC7036118
- OpenAlex
- W3005953215
- Cited by
- 122
- References
- 86
- Citations by year
- 2026: 7 · 2025: 24 · 2024: 25 · 2023: 23 · 2022: 24 · 2021: 13 · 2020: 6
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Pain Research and Management (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Keywords
- fibromyalgia, pharmacotherapy, pregabalin, duloxetine, milnacipran, conditioned pain modulation, cognitive impairment, pain processing, cannabinoid therapy, opioid therapy, personalized treatment, functional imaging
- MeSH terms
- Analgesics, Female, Fibromyalgia, Humans, Chronic Pain, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
